Corrigendum to “Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy”: Annals of Oncology 2020; 31, suppl.4: S472 (abstr. 540P)

S.V. Liu,F. De Braud,A. Drilon, R.C. Doebele, M.R. Patel,B.C. Cho,M.J. Ahn,C.H. Chiu,A.F. Farago, K. Goto, J. Lee, Y. Ohe, S.H.I. Ou, P. Cassier, D.S.W. Tan, G.A. Otterson,L. Veronese,S. Osborne,B. Simmons, S. Siena

user-5f8411ab4c775e9685ff56d3（2021）

引用 0|浏览10

暂无评分

关键词

Entrectinib,non-small cell lung cancer (NSCLC),ROS1 Fusion Positive,Oncology,Medicine,In patient,Internal medicine,Line of therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要